Navigation Links
Vanda Pharmaceuticals Reports Second Quarter 2013 Results
Date:7/31/2013

WASHINGTON, July 31, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the second quarter ended June 30, 2013.

Key Highlights:

  • On July 29, 2013 Vanda announced that the U.S. Food and Drug Administration (FDA) accepted the filing and granted priority review classification to Vanda's New Drug Application (NDA) for tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.
  • The FDA determined the action target date under Prescription Drug User Fee Act (PDUFA-V) to be January 31, 2014.  The FDA has also tentatively scheduled an advisory committee meeting to discuss the tasimelteon application on November 14, 2013.
  • Full year 2013 decrease in cash, cash equivalents and marketable securities (Cash) is expected to be between $45.0 and $50.0 million, consistent with prior guidance.
  • Vanda recorded second quarter 2013 revenue of $8.3 million including royalties of $1.6 million.  Fanapt® prescriptions, as reported by IMS, were approximately 41,400 for the second quarter of 2013.  This represents a 11% increase over second quarter 2012 prescriptions and a 7% increase over first quarter 2013 prescriptions.
  • SECOND QUARTER 2013 REPORTED RESULTSTotal revenues for the second quarter of 2013 were $8.3 million, compared to $8.4 million for the same period in 2012.  Second quarter 2013 revenues included $1.6 million in Fanapt® royalties received from Novartis as compared to royalties of $1.7 million for the second quarter of 2012.

    Total operating expenses for the second quarter of 2013 were $11.4 million, compared to $16.5 million for the second quarter of 2012.  The primary driver of the lower expenses in the second quarter of 2013 was the completion of the tasimelteon Non-24 and Major Depressive Disorder efficacy studies.

    Vanda recorded a net loss of $3.1 million for the second quarter of 2013, compared to a net loss of $8.0 million for the same period in 2012.  Diluted net loss per share for the second quarter of 2013 was $0.11, compared to a diluted net loss per share of $0.28 for the second quarter of 2012.

    Cash, cash equivalents and marketable securities (Cash) decreased by $7.3 million in the second quarter of 2013, compared to decreases of $12.5 million in the second quarter of 2012 and $9.5 million in the first quarter of 2013.  Vanda's Cash as of June 30, 2013 totaled $103.6 million.  

    Year to Date June 30, 2013 Key Financial Figures1 

    Six Months EndedJune 30June 30($ in thousands, except per share amounts)20132012  Change ($)Change (%)Total revenues

    $
    ,387$
    ,519$
    (132)(1%)Research & development  expenses

    13,94224,670(10,728)(43%)General & administrative expenses

    9,0327,5101,52220%Non-cash stock-based compensation2

    1,7822,595(813)(31%)Net loss

    (7,252)(15,969)8,71755%Diluted net loss per share

    $
    (0.26)$
    (0.57)$
    .3154% 

    Second Quarter 2013 Key Financial Figures1 

    Three Months EndedJune 30March 31($ in thousands, except per share amounts)20132013  Change ($)Change (%)Total revenues

    $
    8,319$
    8,068$
    2513%Research & development  expenses

    5,9827,960(1,978)(25%)General & administrative expenses

    5,0743,9581,11628%Non-cash stock-based compensation2

    830952(122)(13%)Net loss

    (3,079)(4,173)1,09426%Diluted net loss per share

    $
    (0.11)$
    (0.15)$
    .0427% 

    Select Cash Flow Data1 Six Months EndedJune 30June 30($ in thousands)20132012Net cash provided by (used in)Operating activities

    $
    (17,168)$
    (20,904)Investing activities

    31,42827,369Financing activities

    601- 

    Select Balance Sheet Data1 June 30March 31June 30($ in thousands)201320132012Total cash and marketable securities

    $
    3,633$
    ,932$
    44,701(1) Unaudited (2) Non-cash stock-based compensation is allocated to both Research & development and General & administrative expenses  

    OPERATIONAL HIGHLIGHTSOn July 29, 2013, Vanda announced that the FDA accepted the filing and granted a priority review classification to Vanda's NDA for tasimelteon, a circadian regulator for the treatment of Non-24 in the totally blind.  Currently, there is no approved treatment for Non-24 and tasimelteon has the potential to address this unmet medical need. The FDA determined the action target date under Prescription Drug User Fee Act (PDUFA-V), to be January 31, 2014.  The FDA has also tentatively scheduled an advisory committee meeting to discuss the tasimelteon application on November 14, 2013.

    Vanda continues to expand its activities in support of Non-24 disease awareness and education with professional, advocacy and patient groups.  In June 2013, Vanda presented data from the SET and RESET studies at the 27th Annual Meeting of the Associated Professional Sleep Societies, SLEEP 2013, and the 95th Annual Endocrine Society Meeting, ENDO 2013.Vanda recorded second quarter 2013 revenue of $8.3 million including $6.7 million in licensing revenue related to the amortization of the upfront payment received from Novartis for U.S. and Canadian commercial rights to Fanapt® and Fanapt® royalties of $1.6 million.  Fanapt® prescriptions, as reported by IMS, were approximately 41,400 for the second quarter of 2013.  This represents a 11% increase over second quarter 2012 prescriptions and a 7% increase versus first quarter 2013 prescriptions.AFFIRMS 2013 FINANCIAL GUIDANCEConsistent with prior guidance, 2013 expenses are expected to reflect lower research and development spending as compared to 2012 and an increase in commercial spending.

  • Full year 2013 decrease in Cash is expected to be between $45.0 and $50.0 million, compared to $47.5 million for 2012.
  • Total 2013 operating expenses are expected to be between $57.0 and $62.0 million.  This includes Fanapt® intangible asset amortization of $1.5 million and $4.0 to $6.0 million of non-cash stock based compensation.
    Total 2012 operating expenses were $61.0 million.
  • 2013 operating expense guidance includes $3.5 million in milestone payments due upon the acceptance by the FDA of a tasimelteon NDA submission and assumes $4.0 to $5.0 million in NDA filing-related expenses.
  • CONFERENCE CALLVanda has scheduled a conference call for today, Wednesday, July 31, 2013, at 10:00 AM ET.  During the call, Vanda's management will discuss the second quarter 2013 financial results and other corporate activities.  Investors can call 1-888-895-5479 (domestic) and 1-847-619-6250 (international) and use passcode 35347357.  A replay of the call will be available beginning Wednesday, July 31, 2013 at 12:00 PM ET and will be accessible until Wednesday, August 7, 2013, at 5:00 PM ET.  The replay call-in number is 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers.  The access number is 35347357.

    The conference call will be broadcast simultaneously on Vanda's website, www.vandapharma.com.  Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations.  The call will also be archived on Vanda's website for a period of 30 days.

    ABOUT VANDA PHARMACEUTICALS INC.:Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit www.vandapharma.com.

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 
    Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.  Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: Vanda's failure to obtain, or any delay in obtaining, regulatory approval for tasimelteon for the treatment of Non-24-Hour Disorder or to comply with ongoing regulatory requirements; the costs and effects of current or potential litigation and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2012 which is on file with the SEC and available on the SEC's website at www.sec.gov.  In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results.  There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda.  Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

    All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein.  Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf.  The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. 

     VANDA PHARMACEUTICALS INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)Three Months EndedSix Months EndedJune 30June 30June 30June 30($ in thousands, except per share amounts)

    2013201220132012Revenues:Licensing agreement$

    6,678$

    6,678$

    13,284$

    13,284Royalty revenue1,6411,7003,1033,235Total revenues8,3198,37816,38716,519Operating expenses:Research and development5,98212,49013,94224,670General and administrative5,0743,6019,0327,510Intangible asset amortization372372741741Total operating expenses11,42816,46323,71532,921Loss from operations(3,109)(8,085)(7,328)(16,402)Other income307876433Loss before tax benefit(3,079)(8,007)(7,252)(15,969)Tax benefit----Net loss$

    (3,079)$

    (8,007)$

    (7,252)$

    (15,969)Net loss per share:Basic$

    (0.11)$

    (0.28)$

    (0.26)$

    (0.57)Diluted$

    (0.11)$

    (0.28)$

    (0.26)$

    (0.57)Shares used in calculations of net lossper share:Basic 28,377,25428,226,74328,361,34028,226,743Diluted28,377,25428,226,74328,361,34028,226,743 

     VANDA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)($ in thousands)June 30, 2013December 31, 2012ASSETSCurrent assets:Cash and cash equivalents$

    103,633$

    88,772Marketable securities-31,631Accounts receivable1,6411,168Prepaid expenses and other current assets2,6513,967Restricted cash, current430430Total current assets108,355125,968Property and equipment, net2,2082,348Intangible asset, net5,7916,532Restricted cash, non-current600600Total assets$

    116,954$

    135,448LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$

    1,167$

    287Accrued liabilities3,7705,187Deferred rent, current209-Deferred revenues, current26,78926,789Total current liabilities31,93532,263Deferred rent, non-current3,0023,005Deferred revenues, non-current76,99190,275Total liabilities111,928125,543Stockholders' equity:Common stock2828Additional paid-in capital303,357300,974Accumulated other comprehensive income-10Accumulated deficit(298,359)(291,107)Total stockholders' equity5,0269,905Total liabilities and stockholders' equity$

    116,954$

    135,448 

    COMPANY CONTACT:
    Jim Kelly 
    Senior Vice President & Chief Financial Officer 
    Vanda Pharmaceuticals Inc. 
    (202) 734-3428 
    jim.kelly@vandapharma.com


    '/>"/>
    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
    2. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
    3. Vanda Pharmaceuticals, Inc. Sued by Investor
    4. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
    5. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
    6. Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
    7. Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
    8. Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
    9. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
    10. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
    11. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
    (Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
    (Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
    Breaking Medicine Technology:
    (Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
    (Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
    (Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
    (Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
    (Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
    Breaking Medicine News(10 mins):